-
AstraZeneca: Yingfeifan combined chemotherapy approved in China as the first immunotherapy regimen for advanced biliary cancer patients
On November 14th, AstraZeneca announced that Infineon&Co; Reg; (English trade name: IMFINZI®, common name: Duvalizumab) has officially obtained approval from the National Drug Administration on N ... -
The FDA in the United States has accepted a supplementary marketing application for the treatment of locally advanced or metastatic solid tumor patients with NTRK positivity using reprotinib
According to the official WeChat account of Zaiding Pharmaceuticals, its partner, Bristol Myers Squibb, announced on February 14th that the US Food and Drug Administration (FDA) has accepted Augtro's ...